These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
345 related articles for article (PubMed ID: 31451044)
1. Fecal DNA Testing for Colorectal Cancer Screening. Carethers JM Annu Rev Med; 2020 Jan; 71():59-69. PubMed ID: 31451044 [TBL] [Abstract][Full Text] [Related]
2. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults. Sharma T Public Health; 2020 May; 182():70-76. PubMed ID: 32179290 [TBL] [Abstract][Full Text] [Related]
3. PPV and Detection Rate of mt-sDNA Testing, FIT, and CT Colonography for Advanced Neoplasia: A Hierarchic Bayesian Meta-Analysis of the Noninvasive Colorectal Screening Tests. Pickhardt PJ; Correale L; Hassan C AJR Am J Roentgenol; 2021 Oct; 217(4):817-830. PubMed ID: 33703913 [No Abstract] [Full Text] [Related]
4. Multitarget Stool DNA Test Performance in an Average-Risk Colorectal Cancer Screening Population. Bosch LJW; Melotte V; Mongera S; Daenen KLJ; Coupé VMH; van Turenhout ST; Stoop EM; de Wijkerslooth TR; Mulder CJJ; Rausch C; Kuipers EJ; Dekker E; Domanico MJ; Lidgard GP; Berger BM; van Engeland M; Carvalho B; Meijer GA Am J Gastroenterol; 2019 Dec; 114(12):1909-1918. PubMed ID: 31764091 [TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia. Ladabaum U; Mannalithara A Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556 [TBL] [Abstract][Full Text] [Related]
6. Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients. Prince M; Lester L; Chiniwala R; Berger B World J Gastroenterol; 2017 Jan; 23(3):464-471. PubMed ID: 28210082 [TBL] [Abstract][Full Text] [Related]
7. A novel multitarget stool DNA test for colorectal cancer screening. Malik P Postgrad Med; 2016; 128(2):268-72. PubMed ID: 26753807 [TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Multitarget Stool DNA Testing vs Colonoscopy or Fecal Immunochemical Testing for Colorectal Cancer Screening in Alaska Native People. Redwood DG; Dinh TA; Kisiel JB; Borah BJ; Moriarty JP; Provost EM; Sacco FD; Tiesinga JJ; Ahlquist DA Mayo Clin Proc; 2021 May; 96(5):1203-1217. PubMed ID: 33840520 [TBL] [Abstract][Full Text] [Related]
9. Performance of multitarget stool DNA testing in African American patients. Cooper GS; Markowitz SD; Chen Z; Tuck M; Willis JE; Berger BM; Brenner DE; Li L Cancer; 2018 Oct; 124(19):3876-3880. PubMed ID: 30193399 [TBL] [Abstract][Full Text] [Related]
10. Stool DNA Testing for Screening Detection of Colorectal Neoplasia in Alaska Native People. Redwood DG; Asay ED; Blake ID; Sacco PE; Christensen CM; Sacco FD; Tiesinga JJ; Devens ME; Alberts SR; Mahoney DW; Yab TC; Foote PH; Smyrk TC; Provost EM; Ahlquist DA Mayo Clin Proc; 2016 Jan; 91(1):61-70. PubMed ID: 26520415 [TBL] [Abstract][Full Text] [Related]
11. Impact of the serrated pathway on the simulated comparative effectiveness of colorectal cancer screening tests. Meester RGS; Ladabaum U JNCI Cancer Spectr; 2024 Sep; 8(5):. PubMed ID: 39240660 [TBL] [Abstract][Full Text] [Related]
12. Multitarget stool DNA test: clinical performance and impact on yield and quality of colonoscopy for colorectal cancer screening. Johnson DH; Kisiel JB; Burger KN; Mahoney DW; Devens ME; Ahlquist DA; Sweetser S Gastrointest Endosc; 2017 Mar; 85(3):657-665.e1. PubMed ID: 27884518 [TBL] [Abstract][Full Text] [Related]
13. Specificity of the Multi-Target Stool DNA Test for Colorectal Cancer Screening in Average-Risk 45-49 Year-Olds: A Cross-Sectional Study. Imperiale TF; Kisiel JB; Itzkowitz SH; Scheu B; Duimstra EK; Statz S; Berger BM; Limburg PJ Cancer Prev Res (Phila); 2021 Apr; 14(4):489-496. PubMed ID: 33436397 [TBL] [Abstract][Full Text] [Related]
14. Multitarget stool DNA testing for colorectal-cancer screening. Imperiale TF; Ransohoff DF; Itzkowitz SH; Levin TR; Lavin P; Lidgard GP; Ahlquist DA; Berger BM N Engl J Med; 2014 Apr; 370(14):1287-97. PubMed ID: 24645800 [TBL] [Abstract][Full Text] [Related]
15. Colonoscopy Findings in FIT+ and mt-sDNA+ Patients versus in Colonoscopy-only Patients: New Hampshire Colonoscopy Registry Data. Anderson JC; Robinson CM; Hisey W; Limburg PJ; Butterly LF Cancer Prev Res (Phila); 2022 Jul; 15(7):455-464. PubMed ID: 35378546 [TBL] [Abstract][Full Text] [Related]
16. Detection of colorectal serrated polyps by stool DNA testing: comparison with fecal immunochemical testing for occult blood (FIT). Heigh RI; Yab TC; Taylor WR; Hussain FT; Smyrk TC; Mahoney DW; Domanico MJ; Berger BM; Lidgard GP; Ahlquist DA PLoS One; 2014; 9(1):e85659. PubMed ID: 24465639 [TBL] [Abstract][Full Text] [Related]
17. Noninvasive fecal testing for colorectal cancer. Zou J; Xiao Z; Wu Y; Yang J; Cui N Clin Chim Acta; 2022 Jan; 524():123-131. PubMed ID: 34756863 [TBL] [Abstract][Full Text] [Related]
18. Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening. Engel-Nitz NM; Miller-Wilson LA; Le L; Fisher DA Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):843-852. PubMed ID: 37462667 [TBL] [Abstract][Full Text] [Related]
19. Detection of High-Risk Sessile Serrated Lesions: Multitarget Stool DNA Versus CT Colonography. Deiss-Yehiely N; Graffy PM; Weigman B; Hassan C; Matkowskyj KA; Pickhardt PJ; Weiss JM AJR Am J Roentgenol; 2022 Apr; 218(4):670-676. PubMed ID: 34755523 [No Abstract] [Full Text] [Related]
20. Impact of Patient Adherence to Stool-Based Colorectal Cancer Screening and Colonoscopy Following a Positive Test on Clinical Outcomes. Fendrick AM; Fisher DA; Saoud L; Ozbay AB; Karlitz JJ; Limburg PJ Cancer Prev Res (Phila); 2021 Sep; 14(9):845-850. PubMed ID: 34021023 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]